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Abstract: (144 words)  
Objective. 
LGR5 is pivotal to oral cavity development and is implicated in epithelial malignancy 
whereby stimulation of LGR5 potentiates canonical Wnt signalling. This investigation tested 
our hypothesis of a correlation between LGR5 expression and the severity of oral epithelial 
dysplasia (OED) and oral squamous cell carcinoma (OSCC).  
Study Design. 
Immunoreactive LGR5 protein expression was quantified in 342 tissue samples ranging in 
disease severity from normal through mild and moderate/severe OED to OSCC.  
Results. 
LGR5 was restricted to the basal layers for normal tissues, projected to the stratum 
granulosum in severe dysplasia, was intense in carcinoma nests of well differentiated OSCC, 
but uniformly diffuse throughout poorly differentiated OSCC. Median LGR5 
immunoreactivity index scores increased with disease severity: mild dysplasia = 1 < 
moderate/severe dysplasia = 2.5 < OSCC = 6. 
Conclusion. 
Inclusion of LGR5 in a panel of immunohistochemical biomarkers may improve identification 
of increased potential for malignancy in OED. 
 
 
 
Clinical Significance (40 words) 
This is the first report of increased LGR5 receptor IHC stain intensity correlating with disease 
severity for Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. LGR5 
immunostaining (perhaps combined with p53 staining) may improve prognostic evaluation 
of oral malignant transformation.  
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Introduction 
Oral squamous cell carcinoma (OSCC) accounts for 90% of oral malignancy and with an 
annual incidence of 275000 it ranks as sixth most common cancer worldwide. Known risk 
factors include habitual exposure to alcohol, tobacco and betel quid, and optimal clinical 
intervention occurs prior to malignancy when patients present with oral potentially 
malignant lesions (OPML).
1
 
Molecular profiling of high incidence malignancies has disclosed gene products with 
potential application for OPML and OSCC disease stratification. Of particular interest are 
stem cell associated molecular markers with proven relevance to rectal cancer,
2
 since rectal 
and oral tissues share features of embryologic development involving endodermal and 
ectodermal derived stem cells 
3
 that persist throughout adulthood and may contribute to 
neoplasia.
4
 
The putative cancer stem cell marker LGR5 (leucine-rich repeat-containing G-protein 
coupled receptor 5) is elevated in colorectal cancer 
5
 and plays a pivotal role in embryologic 
development of the oral cavity where it orchestrates formation of the tongue from the 
foregut endoderm.
6, 7
 Ablation of LGR5 is lethal in-utero but otherwise would cause 
complete ankyloglossia whereby the tongue does not separate from the floor of mouth.
6
 
Figure 1 summarises the integration of LGR5 with the canonical Wnt signaling pathway. The 
functional agonists for LGR5 are four small secreted proteins that comprise the R-spondin 
family (RSPO1-4) which act synergistically with Wnt agonists during embryogenesis and 
oncogenesis to modulate cellular proliferation, differentiation and to maintain the stem cell 
phenotype.
8-10
  
Given that LGR5 activation potentiates Wnt signalling 
8
 to drive stem cell maintenance 
10
 
and oncogenesis,
9
 and that LGR5 is elevated in colorectal cancer 
5
 and is pivotal to oral 
tissue embryogenesis, we hypothesise a correlation between LGR5 expression andthe  
severity of oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). This 
study compared LGR5 immunoreactive protein expression in potentially malignant and 
cancerous oral lesions from 342 formalin fixed paraffin embedded (FFPE) oral biopsies 
bearing a spectrum of disease from normal through mild and moderate/severe dysplasia to 
oral squamous cell carcinoma (OSCC).   
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Materials & Methods 
Patient samples: 342 FFPE specimens: 109 normal mucosa, 43 mild dysplasia (MD), 31 
moderate to severe dysplasia (SD), and 159 oral squamous cell carcinoma (OSCC) were 
obtained from 314 patients: 173 male, 130 female and 11 gender unknown; mean (standard 
deviation) age 55 (18) years. Diagnosis was confirmed retrospectively by an oral pathologist 
(CSF) according to the World Health Organization (WHO) classification system.
11
 The study 
received ethical review and approval from Hospital and University Human Research Ethics 
Committees (HREC/10/QRBW/336 and UQ/2007001478) and was run in accordance with 
the principles outlined by the Declaration of Helsinki. 
Immunohistochemistry (IHC): Performed as described previously. 
12
 Briefly, 5-μm sections 
were incubated overnight at 4°C with rabbit monoclonal anti-LGR5 (#LS-C105455, Lifespan 
Biosciences Inc, WA, USA) diluted 1:1000 in Background Sniper (#BS966M, Biocare Medical, 
Concorde, CA, USA). Staining utilised MACH 2 Universal HRP-Polymer (#M2U522, Biocare 
Medical) with Betazoid DAB chromogen (#BDB2004L, Biocare Medical), CAT haematoxylin 
(#CATHE-M, Biocare Medical) and Leica CV Mount (Leica, Nussloch, Germany). Positive 
staining controls (colon cancer) are available as Supplementary Online Material. Negative 
staining controls were also conducted. 
Scoring: Immumoreactivity was evaluated semi-quantitatively as previously described 
13,14
 
with reference to published guidelines 
15
 by two examiners (LPP and AGM) and confirmed 
independently by a third examiner (AAAM) all of whom were trained and assessed by an 
oral pathologist (CSF). Colon cancer tissues were used as positive staining reference 
material, and reference photomicrographs and slides were used by the examiners to ensure 
consistency of stain intensity scoring. Ten random fields were scored at ×400 magnification, 
counting >500 cells. Cells were firstly evaluated as positive or negative for LGR5, then 
positive cells were graded for intensity of immunoreactivity. Stain intensity was scaled: 0 = 
no stain, 1 = weak intensity, 2 = moderate intensity, 3 = strong intensity. The percent 
positively stained epithelial cells were calculated (numerator = number of positively stained 
cells; denominator = total number of cells observed) and categorised: 0% positive= score 0; 
1-25% positive = score 1; 25-49% positive = score 2; 50-74% positive= score 3; and 75-100% 
positive = score 4. The final index score, which ranged from 0 to 12, was the product of 
categorised percentage positive score and the scaled stain intensity score. 
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Statistical analysis: Non-parametric analysis and presentation used IBM SPSS Statistics V.20 
software (IBM Corporation, Armonk, NY, USA) and the R computing language 
([http://www.R-project.org]). Median (Q2) and inter-quartile range (IQR) have been 
presented. The proportion of positively stained sections has been reported for each 
pathology (numerator = number of positively stained sections; denominator = total number 
of sections observed). Immunolocalisation score data for disease groups were compared to 
normal using Mann-Whitney U tests with Bonferroni correction for n=3 comparisons 
(*p<0.033; ***p<0.003). 
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Results 
LGR5 antigen stain intensity in normal, dysplastic and OSCC biopsies 
LGR5 immunoreactivity is illustrated through representative photomicrographs (Figure 2 A - 
E) and a graphical representation (Figure 2 F). 
The proportion of sections staining positively for LGR5 was lowest for normal tissues (63% 
positive) then increased with disease severity from mild dysplasia (67% positive) through 
moderate/severe dysplasia (74% positive) to OSCC (89% positive).  Similarly, LGR5 antigen 
stain intensity increased with disease severity, a trend that was clearly evident from the 
immunoreactivity index scores:  mild dysplasia (median score = 1; IQR = 0 to 5.3) < 
moderate/severe dysplasia (median score = 2.5; IQR = 0 .5 to 8) < OSCC tissue (median score 
= 6; IQR = 2 to 8.6) (Figure 2F). The pattern of LGR5 immunostaining showed marked 
differences between sample groups (Figure 2 A to E). LGR5 was chiefly restricted to the 
basal layers in normal tissues, sometimes projecting into the stratum spinosum. Greater 
intensity LGR5 immunostaining throughout the stratum spinosum to the stratum 
granulosum typified more severe cases of dysplasia. Well differentiated OSCC samples 
expressed LGR5 at the perimeter of carcinoma nests but not in the keratinised central areas, 
while moderate to poorly differentiated OSCC specimens exhibited LGR5 diffusely 
throughout the carcinoma cells (Figure 2 D & E). 
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Discussion 
This study analysed LGR5 protein expression in 342 FFPE oral biopsies bearing a spectrum of 
disease ranging from normal through mild and moderate/severe dysplasia to oral squamous 
cell carcinoma (OSCC) to test our hypothesis of a correlation between LGR5 expression and 
the pathology grading of these lesions. This hypothesis was supported by demonstration of 
elevated LGR5 expression in OSCC and moderate/severe dysplasia relative to normal oral 
tissues (statistically significant; Mann-Whitney) and the positive trend between LGR5 
immunoscore data and diagnostic grading of OPML severity. Previously, using a sub-group of 
these biopsies (n=100 specimens: 18 normal, 27 mild dysplasia, 8 moderate dysplasia, 47 
OSCC) we demonstrated an equivalent positive trend between cytoplasmic and nuclear β-
catenin immunoscore data and the diagnostic grading of OPML and OSCC.
14
 Cytoplasmic and 
nuclear accumulation of β-catenin is indicative of signal transduction via the canonical Wnt 
signalling pathway (figure 1),
10
 and the mutually supportive findings of these discrete IHC 
studies indicate progressive dysregulation of canonical Wnt signalling in oral malignant 
transformation. The findings of this study suggest potential application of LGR5 expression 
analysis to the diagnostic grading of OPML and OSCC and further supports the hypothesised 
involvement of cancer stem cell marker positive cell populations in tumour formation.
4
 
LGR5 plays a definitive role in the embryologic development of oral tissue 
6, 7
 via its highly 
influential mechanism of action: potentiation of the canonical Wnt signalling pathway.
8-10
 
Early genetic aberrations in OSCC impede p53 and the pRb pathway to promote cell 
immortalisation.
16
 Recently, p53 (and its transcriptional target, miR-34) has been 
demonstrated to be a potent suppressor of Wnt signalling.
17
 This may explain elevated Wnt 
signalling in tumours lacking p53,
18
 and provide a mechanism by which loss of p53 activity 
can promote Wnt signal driven clonal expansion during cancer progression.
19
 Cells with 
elevated LGR5 expression and potentiated Wnt signal response
14
 may exhibit increased 
neoplastic potential following loss of p53 tumour suppressor activity. The pathway shown in 
figure 1 is currently untested and the association between elevated LGR5 expression and 
oral potentially malignant lesion severity shown here does not indicate causality of 
malignant transformation. It is, therefore, too speculative to suggest that a panel of 
molecular biomarkers combining LGR5 with p53 or miR-34 may provide a means to identify 
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increased potential for malignancy in OPML, although further research into this translational 
opportunity is warranted.  
This is the first demonstration of elevated LGR5 expression in OSCC and OPML. This result 
corresponds with our prior report of intracellular β-catenin accumulation in OPML and 
OSCC,
14
 with prior reports of elevated LGR5 expression in colorectal cancer 
5
 and with the 
commonality between rectal and oral tissue embryologic development.
3
 We suggest that 
LGR5 overexpression may contribute to clonal expansion during OSCC development via a 
mechanism that involves LGR5 mediated potentiation of Wnt signaling,
8-10
 p53 tumour 
suppressor mediated inhibition of Wnt signaling,
17
 and abrogation of p53 tumour 
suppressor activity as an early event in OSCC development.
16
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Figure Legends 
 
Figure 1 Simplified schematic of the canonical Wnt signalling pathway showing potentiation 
of signal transduction by LGR5 receptor co-stimulation and the quiescing influence of p53 
tumour suppressor. Resting State: β-catenin (β-Cat) is the principal effector protein of the 
canonical Wnt pathway. It is constitutively synthesised and, in the absence of Wnt signalling, 
β-catenin undergoes proteolysis by a “destruction complex” of cytoplasmic proteins that 
includes tumour suppressors (Axin and APC), Ser/Thr kinases (GSK-3 and CK1), protein 
phosphatases (PP2A), and a ubiquitin ligase (β-TrCP). Signalling Event: Wnt signal instigation 
involves interaction of plasma membrane bound receptors (Frizzled and Lrp5/6) with 
extracellular Wnt agonist. Consequent phosphorylation events recruit the “destruction 
complex” to the membrane where it is disabled; intracellular β-catenin accumulates. 
Cytoplasmic β-catenin enters the nucleous to form a complex with T-cell transcription factor 
(Tcf) which drives the transcription of numerous cell regulatory Wnt target genes. Signal 
Potentiation: Stimulation of membrane bound LGR5 receptor by its agonist (R-spondin) 
significantly amplifies Wnt signal instigation. Pathway Quiescence: Transcription of 
microRNA-34 (miR-34) is promoted by tumour suppressor protein p53. Interaction of miR-34 
with near-complementary target sites in the 5’ and/or 3’ untranslated regions of Wnt target 
gene mRNA transcripts imposes post-transcriptional repression upon numerous Wnt 
targets. Note: this pathway has not yet been investigated with direct reference to OSCC. 
 
Figure 2 LGR5 immunostaining in oral epithelial dysplasia and oral squamous cell carcinoma. 
Representative immunostaining of LGR5 for normal (A; final score 2), mild dysplasia (B; final 
score 3), moderate-severe dysplasia (C; final score 6) well differentiated OSCC (D; final score 
9) and poorly differentiated OSCC (E; final score 12) (original magnification x 100). (F) Box 
and Whisker plots of LGR5 immunoscoring grouped by histopathology in normal oral 
mucosa, mild dysplasia (MD), moderate/severe dysplasia (SD) and OSCC cases showing 
median (bold line), 25th to 75th percentiles (box) and outliers (circles); * p<0.03, *** 
p<0.003 (Mann–Whitney U test). (G and H) show low power (original magnification x 50) 
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haematoxylin & eosin sections of well differentiated and poorly differentiated OSCC shown 
in (D) and (E) respectively.  
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Supplementary Figure: 
Positive control immunostaining for LGR5 in a FFPE section of colon cancer. 
